Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genmab
Biotech
Genmab ph. 2 data spur claim ADC ‘clearly superior’ to Elahere
Genmab reported progression-free survival of 9.5 months, leading TD Cowen analysts to hail the asset as “clearly superior” to AbbVie’s Elahere.
Nick Paul Taylor
Oct 5, 2026 4:14am
J&J junks $1.2B eczema therapy while Genmab drops cancer drug
Jan 2, 2026 9:05am
Genmab sheds another clinical ADC from $1.8B ProfoundBio buy
Nov 17, 2025 2:17pm
Genmab pays $8B to buy Merus and phase 3 bispecific
Sep 29, 2025 5:38am
Genmab discards ADC from $1.8B ProfoundBio buy
Sep 16, 2025 10:33am
Pfizer’s reputation wrangler plans departure—Chutes & Ladders
Jul 11, 2025 8:30am
